Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

18F- FDG PET/CT helps differentiate autoimmune pancreatitis from pancreatic cancer

Authors: Jian Zhang, Guorong Jia, Changjing Zuo, Ningyang Jia, Hui Wang

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

18F-FDG PET/CT could satisfactorily show pancreatic and extra-pancreatic lesions in AIP, which can be mistaken for pancreatic cancer (PC). This study aimed to identify 18F-FDG PET/CT findings that might differentiate AIP from PC.

Methods

FDG-PET/CT findings of 26 AIP and 40 PC patients were reviewed. Pancreatic and extra-pancreatic lesions related findings, including maximum standardized uptake values (SUVmax) and patterns of FDG uptake, were identified and compared.

Results

All 26 patients with AIP had increased pancreatic FDG uptake. Focal abnormal pancreatic FDG activities were found in 38/40 (95.00%) PC patients, while longitudinal were found in 18/26 (69.23%) AIP patients. SUVmax was significantly different between AIP and PC, both in early and delayed PET/CT scans (p < 0.05). AUCs were 0.700 (early SUVmax), 0.687 (delayed SUVmax), 0.683 (early lesions/liver SUVmax), and 0.715 (delayed lesion/liver SUVmax). Bile duct related abnormalities were found in 12/26 (46.15%) AIP and 10/40 (25.00%) PC patients, respectively. Incidentally, salivary and prostate gland SUVmax in AIP patients were higher compared with those of PC patients (p < 0.05). In males,an inverted “V” shaped high FDG uptake in the prostate was more frequent in AIP than PC patients (56.00%, 14/25 vs. 5.71%, 2/35). Increased FDG activity in extra-pancreatic bile duct was present in 4/26 of AIP patients, while was observed in none of the PC patients. Only in AIP patients, both diffuse pancreatic FDG accumulation and increased inverted “V” shaped FDG uptake in the prostate could be found simultaneously.

Conclusions

18F-FDG PET/CT findings might help differentiate AIP from PC.
Literature
1.
Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med. 2006;355:2670–6.CrossRefPubMed
2.
Nakazawa T, Ohara H, Sano H, Ando T, Imai H, Takada H, et al. Difficulty in diagnosing autoimmune pancreatitis by imaging findings. Gastrointest Endosc. 2007;65:99–108.CrossRefPubMed
3.
Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol. 2003;98:2694–9.CrossRefPubMed
4.
Hardacre JM, Iacobuzio-Donahue CA, Sohn TA, Abraham SC, Yeo CJ, Lillemoe KD, et al. Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg. 2003;237:853–8. discussion 8-9PubMedPubMedCentral
5.
Wu LL, Li W. An analysis of clinical characteristics of autoimmune pancreatitis. Zhonghua Nei Ke Za Zhi. 2010;49:943–6.PubMed
6.
Dong A, Dong H, Zhang L, Zuo C. Hypermetabolic lesions of the pancreas on FDG PET/CT. Clin Nucl Med. 2013;38:e354–66.CrossRefPubMed
7.
Shigekawa M, Yamao K, Sawaki A, Hara K, Takagi T, Bhatia V, et al. Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis? J Hepatobiliary Pancreat Sci. 2010;17:269–74.CrossRefPubMed
8.
Lee TY, Kim MH, Park DH, Seo DW, Lee SK, Kim JS, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol. 2009;193:343–8.CrossRefPubMed
9.
Ozaki Y, Oguchi K, Hamano H, Arakura N, Muraki T, Kiyosawa K, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144–51.CrossRefPubMed
10.
Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging. 2007;34:2088–95.CrossRefPubMed
11.
Sato M, Okumura T, Shioyama Y, Imura J. Extrapancreatic F-18 FDG accumulation in autoimmune pancreatitis. Ann Nucl Med. 2008;22:215–9.CrossRefPubMed
12.
Jian Z. Imaging characteristics of autoimmune pancreatitis: F-18-FDG PET/CT versus Contrast Enhanced CT. J Nucl Med. 2015;56
13.
Zhang J, Shao C, Wang J, Cheng C, Zuo C, Sun G, et al. Autoimmune pancreatitis: whole-body 18F-FDG PET/CT findings. Abdom Imaging. 2013;38:543–9.CrossRefPubMed
14.
Zhang L, Chari S, Smyrk TC, Deshpande V, Kloppel G, Kojima M, et al. Autoimmune pancreatitis (AIP) type 1 and type 2: an international consensus study on histopathologic diagnostic criteria. Pancreas. 2011;40:1172–9.CrossRefPubMed
15.
Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–8.CrossRefPubMed
16.
Lee LK, Sahani DV. Autoimmune pancreatitis in the context of IgG4-related disease: review of imaging findings. World J Gastroenterol. 2014;20:15177–89.CrossRefPubMedPubMedCentral
17.
18.
Sugumar A, Chari S. Autoimmune pancreatitis: an update. Expert Rev Gastroenterol Hepatol. 2009;3:197–204.CrossRefPubMed
19.
Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Pedrazzoli S. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg. 2005;9:22–8. discussion 8-9CrossRefPubMed
20.
Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259–64.CrossRefPubMed
21.
Balink H, Tan SS, Veeger NJ, Holleman F, van Eck-Smit BL, Bennink RJ, et al. (1)(8)F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study. Eur J Nucl Med Mol Imaging. 2015;42:1408–13.CrossRefPubMed
22.
Imdahl A, Nitzsche E, Krautmann F, Hogerle S, Boos S, Einert A, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg. 1999;86:194–9.CrossRefPubMed
23.
Nakatani K, Nakamoto Y, Togashi K. Utility of FDG PET/CT in IgG4-related systemic disease. Clin Radiol. 2012;67:297–305.CrossRefPubMed
24.
Horiuchi A, Kawa S, Hamano H, Hayama M, Ota H, Kiyosawa K. ERCP features in 27 patients with autoimmune pancreatitis. Gastrointest Endosc. 2002;55:494–9.CrossRefPubMed
25.
26.
Jian Z. Comparsion of Positron Emission Tomography/Computed Tomography and Contrast-Enhanced Computed Tomography in Lung Cancer Lymph Node Staging. J Nucl Med. 2015;56:1385.
Metadata
Title
18F- FDG PET/CT helps differentiate autoimmune pancreatitis from pancreatic cancer
Authors
Jian Zhang
Guorong Jia
Changjing Zuo
Ningyang Jia
Hui Wang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3665-y

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer

Research article

Circadian disruption promotes tumor growth by anabolic host metabolism; experimental evidence in a rat model

Research article

The feasibility and advantage of uniportal video-assisted thoracoscopic surgery (VATS) in pulmonary lobectomy

Research article

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Research article

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer

Research article

Improving adherence to colorectal cancer surveillance guidelines: results of a randomised controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits